JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

Home・Lista de Ações・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Fechado

SetorSaúde

40.7 -0.93

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

40.7

Máximo

41.06

Indicadores-chave
By Trading Economics
Rendimento	-20M -85M
Margem de lucro	-867.293
Funcionários	316
EBITDA	-21M -94M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+36.38% upside

Dividendos
By Dow Jones
Próximos Ganhos	12 de nov. de 2025

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	732M 3.3B
Abertura anterior	41.63
Fecho anterior	40.7

Sentimento de Notícias

By Acuity

67%

33%

319 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

34.81 / 38.24 Suporte e Resistência

Xenon Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de out. de 2025, 18:41 UTC

Ganhos

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 de out. de 2025, 18:31 UTC

Ganhos

Correction to Procter & Gamble to Focus on Innovation

24 de out. de 2025, 16:25 UTC

Grandes Movimentos do Mercado

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 de out. de 2025, 21:24 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

24 de out. de 2025, 21:24 UTC

Conversa de Mercado

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 de out. de 2025, 21:07 UTC

Ganhos

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 de out. de 2025, 20:58 UTC

Ganhos

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 de out. de 2025, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

24 de out. de 2025, 20:40 UTC

Ganhos

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 de out. de 2025, 20:24 UTC

Ganhos

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 de out. de 2025, 20:23 UTC

Ganhos

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 de out. de 2025, 20:13 UTC

Ganhos

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 de out. de 2025, 20:07 UTC

Conversa de Mercado

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 de out. de 2025, 19:40 UTC

Conversa de Mercado

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 de out. de 2025, 19:35 UTC

Conversa de Mercado

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 de out. de 2025, 19:33 UTC

Ganhos

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 de out. de 2025, 19:29 UTC

Conversa de Mercado

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 de out. de 2025, 18:52 UTC

Ganhos

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 de out. de 2025, 18:41 UTC

Ganhos

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 de out. de 2025, 18:03 UTC

Ganhos

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 de out. de 2025, 18:02 UTC

Ganhos

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 de out. de 2025, 18:00 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 de out. de 2025, 16:57 UTC

Ganhos

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 de out. de 2025, 16:54 UTC

Conversa de Mercado

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 de out. de 2025, 16:44 UTC

Conversa de Mercado

Ganhos

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 de out. de 2025, 16:39 UTC

Conversa de Mercado

Ganhos

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 de out. de 2025, 16:33 UTC

Ganhos

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 de out. de 2025, 16:23 UTC

Ganhos

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 de out. de 2025, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

24 de out. de 2025, 16:07 UTC

Ganhos

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Comparação entre Pares

Variação de preço

Xenon Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

36.38% parte superior

Previsão para 12 meses

Média 55.59 USD 36.38%

Máximo 65 USD

Mínimo 48 USD

Com base em 14 analistas de Wall Street que oferecem metas de preço de 12 meses para Xenon Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

14 ratings

Comprar

Manter

Vender

Com base em 14 analistas que deram avaliações de ações para Xenon Pharmaceuticals Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

34.81 / 38.24Suporte e Resistência

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentimento

By Acuity

319 / 371 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.